Vanessa A. Giunta
- BIOGRAPHY
- Insights
Vanessa Giunta joined Garfunkel Wild, P.C. in 2022. She works on regulatory, corporate, and transactional matters for clients including, but not limited to, hospitals, medical providers, ambulatory care facilities, physician practices, and other for-profit and not-for-profit entities. Vanessa also has experience working on clinical trial and grant award agreements with research sponsors.
Prior to joining the firm, Vanessa was a Public Health Law Program Legal Intern at the Centers for Disease Control and Prevention, a Research Fellow at the Gitenstein Institute for Health Law and Policy, and a Clinic Intern at the Robert W. Entenmann Veterans Law Clinic. Vanessa was also a Certified Pharmacy Technician at local pharmacy companies and a Director of Reimbursement for a long term care pharmacy.
While in law school, Vanessa had her Note published in the Hofstra Labor & Employment Law Journal and received the highest level of Hofstra Law’s Public Service Awards for completing over 750 hours of public service work.
Last week, the U.S. Department of Justice (DOJ) and the U.S. Department of Health and Human Services (HHS) released its annual, jointly authored Health Care Fraud and Abuse Control Program Report (the Report) for Fiscal Year 2023.
What is the Status of the Pending FTC Ban on Non-Compete Agreements? Many clients are asking whether the Federal Trade Commission (FTC) ban has gone into effect and, if not, what the status is currently. As we reported previously, click HERE, the FTC enacted a nationwide ban on most non-compete agreements, subject to certain narrow exceptions, […]
Pharmacy revocations for non-compliance with Medicare Part B and Durable Medical Equipment, Prosthetics, Orthotics and Supplies enrollment requirements are on the rise. Garfunkel Wild’s latest webinar in our Compliance Webinar Series discusses common risks and provides strategies to protect your pharmacy.
The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (24-03) permitting a pharmaceutical manufacturer (Manufacturer) to provide financial assistance to qualified patients undergoing its gene therapy treatment for two severe genetic conditions.
Garfunkel’s Compliance Webinar Series rolls on with an examination of the 2024 Work Plan published by the New York State Office of Medicaid Inspector General (OMIG).
On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) promulgated a final rule banning most non-compete agreements, in any industry, and is set to become effective 120 days after its publication in the Federal Register (the “Final Rule”).
The New York State Office of the Medicaid Inspector General (OMIG) released its 2024 work plan in furtherance of its mission to coordinate and conduct activities to prevent, detect and investigate medical assistance program fraud, waste and abuse, and to recover improperly expended Medicaid funds.
The U.S. Department of Health and Human Services, Office of Inspector General (OIG) released a new toolkit to help Medicare Advantage (MA) organizations replicate OIG audit methodologies to detect and correct inaccurate diagnosis codes in their own systems.
The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (23-12) that allows a limited liability partnership (the Partnership) consisting of two classes of physician partners to make a one-time, voluntary redemption offer (offer) to individual partners when they reach age 67.
Scammers have perpetuated a telephone fraud scheme attempting to extort money and personal identifiable information from healthcare providers by impersonating Drug Enforcement Administration (“DEA”) agents across the country.
Vanessa Giunta joined Garfunkel Wild, P.C. in 2022. She works on regulatory, corporate, and transactional matters for clients including, but not limited to, hospitals, medical providers, ambulatory care facilities, physician practices, and other for-profit and not-for-profit entities. Vanessa also has experience working on clinical trial and grant award agreements with research sponsors.
Prior to joining the firm, Vanessa was a Public Health Law Program Legal Intern at the Centers for Disease Control and Prevention, a Research Fellow at the Gitenstein Institute for Health Law and Policy, and a Clinic Intern at the Robert W. Entenmann Veterans Law Clinic. Vanessa was also a Certified Pharmacy Technician at local pharmacy companies and a Director of Reimbursement for a long term care pharmacy.
While in law school, Vanessa had her Note published in the Hofstra Labor & Employment Law Journal and received the highest level of Hofstra Law’s Public Service Awards for completing over 750 hours of public service work.
Pharmacy revocations for non-compliance with Medicare Part B and Durable Medical Equipment, Prosthetics, Orthotics and Supplies enrollment requirements are on the rise. Garfunkel Wild’s latest webinar in our Compliance Webinar Series discusses common risks and provides strategies to protect your pharmacy.
The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (24-03) permitting a pharmaceutical manufacturer (Manufacturer) to provide financial assistance to qualified patients undergoing its gene therapy treatment for two severe genetic conditions.
Garfunkel’s Compliance Webinar Series rolls on with an examination of the 2024 Work Plan published by the New York State Office of Medicaid Inspector General (OMIG).
On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) promulgated a final rule banning most non-compete agreements, in any industry, and is set to become effective 120 days after its publication in the Federal Register (the “Final Rule”).
The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (23-12) that allows a limited liability partnership (the Partnership) consisting of two classes of physician partners to make a one-time, voluntary redemption offer (offer) to individual partners when they reach age 67.
The U.S. Department of Health and Human Services, Office of Inspector General (OIG) released a new toolkit to help Medicare Advantage (MA) organizations replicate OIG audit methodologies to detect and correct inaccurate diagnosis codes in their own systems.
The New York State Office of the Medicaid Inspector General (OMIG) released its 2024 work plan in furtherance of its mission to coordinate and conduct activities to prevent, detect and investigate medical assistance program fraud, waste and abuse, and to recover improperly expended Medicaid funds.
Scammers have perpetuated a telephone fraud scheme attempting to extort money and personal identifiable information from healthcare providers by impersonating Drug Enforcement Administration (“DEA”) agents across the country.
What is the Status of the Pending FTC Ban on Non-Compete Agreements? Many clients are asking whether the Federal Trade Commission (FTC) ban has gone into effect and, if not, what the status is currently. As we reported previously, click HERE, the FTC enacted a nationwide ban on most non-compete agreements, subject to certain narrow exceptions, […]
Last week, the U.S. Department of Justice (DOJ) and the U.S. Department of Health and Human Services (HHS) released its annual, jointly authored Health Care Fraud and Abuse Control Program Report (the Report) for Fiscal Year 2023.
Last week, the U.S. Department of Justice (DOJ) and the U.S. Department of Health and Human Services (HHS) released its annual, jointly authored Health Care Fraud and Abuse Control Program Report (the Report) for Fiscal Year 2023.
What is the Status of the Pending FTC Ban on Non-Compete Agreements? Many clients are asking whether the Federal Trade Commission (FTC) ban has gone into effect and, if not, what the status is currently. As we reported previously, click HERE, the FTC enacted a nationwide ban on most non-compete agreements, subject to certain narrow exceptions, […]
Pharmacy revocations for non-compliance with Medicare Part B and Durable Medical Equipment, Prosthetics, Orthotics and Supplies enrollment requirements are on the rise. Garfunkel Wild’s latest webinar in our Compliance Webinar Series discusses common risks and provides strategies to protect your pharmacy.
The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (24-03) permitting a pharmaceutical manufacturer (Manufacturer) to provide financial assistance to qualified patients undergoing its gene therapy treatment for two severe genetic conditions.
Garfunkel’s Compliance Webinar Series rolls on with an examination of the 2024 Work Plan published by the New York State Office of Medicaid Inspector General (OMIG).
On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) promulgated a final rule banning most non-compete agreements, in any industry, and is set to become effective 120 days after its publication in the Federal Register (the “Final Rule”).
The New York State Office of the Medicaid Inspector General (OMIG) released its 2024 work plan in furtherance of its mission to coordinate and conduct activities to prevent, detect and investigate medical assistance program fraud, waste and abuse, and to recover improperly expended Medicaid funds.
The U.S. Department of Health and Human Services, Office of Inspector General (OIG) released a new toolkit to help Medicare Advantage (MA) organizations replicate OIG audit methodologies to detect and correct inaccurate diagnosis codes in their own systems.
The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (23-12) that allows a limited liability partnership (the Partnership) consisting of two classes of physician partners to make a one-time, voluntary redemption offer (offer) to individual partners when they reach age 67.
Scammers have perpetuated a telephone fraud scheme attempting to extort money and personal identifiable information from healthcare providers by impersonating Drug Enforcement Administration (“DEA”) agents across the country.